Parkinson disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• SNCA 10
• LRRK2 7
• NRF2 1
• GBA1 13
• NLRP3 1
• PINK1 1
• AKT 0
• PI3K 0
• GLP-1 0
• STING 0
• BDNF 1
• mTOR 0
• SIRT1 0
• TLR4 0
• PPAR 0
• AMPK 1
• TP53 0
• GPX4 0
• MAPK 0
• MAPT 0
• TNF 0
• APOE 1
• HMGB1 0
• JNK 0
• ERK 0
• HSP90 1
• JAK 0
• STAT3 0
• TREM2 0
• HDAC 0
• TDP-43 1
• NMDA 0
• TFEB 0
• HIF-1 1
• IL-1 0
• PARP 0
• CTNNB1 0
• GIP 0
• IL-17 0
• PCSK9 0
• ACE2 0
• AQP4 0
• BCL-2 0
• CSF1R 0
• FTO 0
• PKM2 0
• SGLT2 0
• CD38 0
• COX-2 0
• DPP-4 0
• G6PD 0
• IDO1 0
• PDE4 0
• PTEN 0
• YAP 0
• ALK 0
• APP 0
• ATM 0
• BACE1 0
• C9orf72 0

24 of 3,889 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• U.S. Department of Veterans Affairs · I01

  Peripheral orexin agonists to improve motor function in a mouse model of Parkinson’s Disease

  Minneapolis Va Medical Center· Minneapolis, United States· until Sept 2030

• U.S. Department of Veterans Affairs · I01

  Clinical and Neuropathological Characterization of Parkinsonism Related to TBI in Veterans (CANPARK-TBI)

  James J Peters Va Medical Center· Bronx, United States· until Sept 2030

• NIH NEI · R01

  Retinal Cell Loss in Diabetic Retinopathy

  Wayne State University· Detroit, United States· US$387,500 awarded in fiscal year 2026· until May 2030

• NIH NIDDK · F31

  Skeletal muscle MIRO1 Mediates Insulin Resistance and Muscular Complications in Type 2 Diabetes

  University of Oklahoma Hlth Sciences Ctr· Oklahoma City, United States· US$50,114 awarded in fiscal year 2026· until Sept 2028

• NIH NCI · F31

  Deciphering RNA Zipcodes: A Novel Framework for Subcellular Localization Element Annotation

  Baylor College of Medicine· Houston, United States· US$50,114 awarded in fiscal year 2026· until Sept 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Multimodal AI-based Clinical prOgnostic Models for PArkinson's Symptoms progression and Subtyping (mAIcompass)

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €435,842· until Nov 2030· 3 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Curation, Integration, Modelling and Rational Design of Small Molecule Amyloid Inhibitors (AmyStoppers)

  Vilniaus Universitetas· Vilnius, Lithuania· EU contribution €196,976· until Mar 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Multi-scAle high-order neTwork modelling in the stUdy of human aging: A data-dRiven perspectIve using Topology and geometrY (MATURITY)

  Institut National de Recherche En Informatique Et Automatique· Le Chesnay Cedex, France· EU contribution €226,421· until Jan 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  ENGINEERING NANOPARTICLE-WATER COUPLING; ionic, hypoxic, logic and molecular contrast switches (WATERGATING)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, United Kingdom· EU contribution €2,113,066· until Dec 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Single-vesicle PlAtform for Real-Time detection of membrane-catalyzed Aggregation and transmission (SPARTA)

  Aarhus Universitet· Aarhus C, Denmark· EU contribution €1,500,000· until Nov 2031

  The disease is named only in the funder's project summary, not in the title.

10 of 1,408 running projects, newest first. Listed amounts together: US$777.6m + €184.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  High-Dose Ambroxol in GBA1-Related Parkinson

  NCT06193421· Agyany Pharma LTD· Updated 9 Nov 2026

  “Sponsor's decision”Registry text, quoted unchanged. Source

• Terminated

  Robotic Gait Rehabilitation in Parkinson's Disease

  NCT05218187· Indiana University· Updated 5 Nov 2026

  “The PI was no longer able to successfully recruit participants and funding was depleted.”Registry text, quoted unchanged. Source

• Terminated

  Tapping Test and the Archimedean Spiral for the Differential Diagnosis of Tremor. Machine Learning Approach

  NCT06378619· Consorci Sanitari de l'Alt Penedès i Garraf· Updated 28 Oct 2026

  “Poor recruitment”Registry text, quoted unchanged. Source

• Terminated

  Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  NCT02897063· Vanderbilt University Medical Center· Updated 23 Oct 2026

  “enrollment goal was not met.”Registry text, quoted unchanged. Source

• Terminated

  Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Disease

  NCT06003608· Nimble Science Ltd.· Updated 20 Oct 2026

  “Study recruitment phase exceeded the time allotted”Registry text, quoted unchanged. Source

• Suspended

  Terazosin And Metabolic Energetics in Parkinson's Disease

  NCT07464028· Ergun Y. Uc· Updated 9 Oct 2026

  “Study not funded”Registry text, quoted unchanged. Source

• Withdrawn

  Terazosin And Metabolic Engagement in Parkinson's Disease

  NCT07288450· Nandakumar Narayanan· Updated 7 Oct 2026

  “Not Funded”Registry text, quoted unchanged. Source

• Terminated

  Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease

  NCT07313176· Britannia Pharmaceuticals Ltd.· Updated 2 Oct 2026

  “Following a reassessment, it was concluded that continuation of the study would no longer achieve its scientific objectives originally set out for the study.”Registry text, quoted unchanged. Source

• Withdrawn

  The Parkinson's Disease Case-Control Study

  NCT06848192· Westlake University· Updated 29 Sept 2026

  “Due to challenges in obtaining faecal samples from patients with Parkinson's disease, a population frequently affected by constipation.”Registry text, quoted unchanged. Source

• Suspended

  Sensory Filtering in the Human Basal Ganglia as a Mechanism of Parkinson's Disease

  NCT05482126· University of Alabama at Birmingham· Updated 24 Sept 2026

  “Suspending since no longer working participants at this time or enrolling new ones.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Stimulating Specific Brain Areas (VOP/VIM) With Electricity to Improve Movement and Muscle Control

  NCT07056361· Jorge Gonzalez-Martinez· Source

• Closed Loop DBS Implanted RC+S Study

  NCT03815656· Dennis Turner, M.D.· Source

• DBS Imaging-based vs. Threshold Assessment-based Programming

  NCT06223399· Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)· Source

• Identification of Cognitive and Motor Changes in Individuals With and Without Parkinson's Disease Using Hemoencephalography

  NCT07931677· Federal University of Uberlandia· Source

• RehaBEElitation - Serious Game-Based Experimental Protocol to Improve Manual Dexterity in Individuals With Parkinson's Disease

  NCT07928050· Federal University of Uberlandia· Source

• Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease

  NCT07781644· Hoffmann-La Roche· Source

• An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

  NCT06996652· Yale University· Source

• Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation

  NCT07642908· University of Michigan· Source

• Voluntary Activation During Isokinetic Contractions in Subjects With Neuromotor Disorders

  NCT04607174· Istituto Auxologico Italiano· Source

• Mobility in Daily Life and Falls in Parkinson's Disease: Potential for Rehabilitation

  NCT04897256· Oregon Health and Science University· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 25
• Organoids 19
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 15
• Gene Expression Profiling 76
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 7
• Exome Sequencing 12
• Proteomics 70
• Metabolomics 35
• Mass Spectrometry 12
• Flow Cytometry 4
• Immunohistochemistry 50
• Liquid Biopsy 3
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 103
• Magnetic Resonance Imaging 369
• Machine Learning 141
• Deep Learning 72
• Cohort Studies 186
• Genome-Wide Association Study 83

• Comparative analysis of single and dual sgRNA CRISPR/Cas9 ribonucleoprotein strategies for efficient Park7 gene editing in primary mouse embryonic fibroblasts.

  Mol Biol Rep, Oct 2026

• CRISPR/Cas9-based nanodelivery systems for precision gene editing in neuroinflammation.

  Inflamm Res, Oct 2026

• CRISPR-dCas13a-based electrochemical biosensor for sensitive detection of miR-331-5p as a potential biomarker of Parkinson's disease.

  Anal Biochem, Sept 2026

• Opto-CRISPR technologies in translational neuropharmacology.

  Neuropharmacology, Sept 2026

• Targeting the hallmarks of ageing: Pharmacological challenges and breakthroughs in CRISPR delivery systems and future prospects.

  Ageing Res Rev, Aug 2026

• Programmable gene modulation networks for Parkinson's disease using nanotechnology enabled CRISPR/Cas brain delivery.

  Int J Pharm, Jul 2026

• iSCORE-PD: an isogenic stem cell collection to research Parkinson's disease.

  Nat Commun, Jun 2026

• CRISPR-Based Gene Therapy for Brain Disease.

  Mol Neurobiol, Jun 2026

• Gene Editing Strategies for Neurological and Mental Disorders: Advances in Delivery, Methodology, and Clinical Translation.

  Cells, Apr 2026

• Human pluripotent stem cell engineering with CRISPR-Cas9 for Parkinson's disease.

  Exp Mol Med, Apr 2026

See which targets of this disease your abstract mentions, and go to the people working on them.